Study of MC002 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called MC002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to find the right dose and see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your cancer is advanced or has spread and standard treatments no longer work
- You are expected to live at least 3 more months
- You have at least one tumor that can be measured on scans
- You are in generally good health aside from cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new cancer drug called NEOK002 that targets two proteins (EGFR and MUC1) found on certain cancer cells. It's designed for patients with advanced cancers that have spread and don't have standard treatment options available.
This trial tests a new drug called BC008-1A for people with advanced esophageal cancer or non-small cell lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
This study tests a new drug called DM005 for people with advanced solid tumors (like lung, stomach, colon, liver, pancreas, or head and neck cancer) that have not responded to or can't tolerate standard treatments. The goal is to see if DM005 is safe and how well it works.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This Phase 1 study tests IMC-002 in people with advanced cancers that did not respond to standard therapy. It may help by trying a new immune-targeting drug approach when other options have failed.
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.